| UNITED STATES | |
| SECURITIES AND EXCHANGE COMMISSION | |
| Washington, D.C. 20549 | |
| Notice of Effectiveness | |
| Effectiveness Date: | May 13, 2025 4:01 P.M. |
| Form: | S-3 | ||||||
| |||||||
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 11/11/2024 | $3.00 | Overweight → Neutral | Piper Sandler |
| 3/28/2024 | $5.00 | Outperform | Oppenheimer |
| 8/28/2023 | $4.50 | Buy | Craig Hallum |
| 10/21/2022 | $4.00 | Buy | Jefferies |
| 4/28/2022 | $6.50 | Buy | Craig Hallum |
| 2/16/2022 | $8.00 → $6.00 | Outperform | SVB Leerink |
| 12/31/2021 | $6.00 → $8.00 | Outperform | SVB Leerink |
| 12/31/2021 | $4.25 → $5.40 | Buy | HC Wainwright & Co. |
4 - Xeris Biopharma Holdings, Inc. (0001867096) (Issuer)
4 - Xeris Biopharma Holdings, Inc. (0001867096) (Issuer)
4 - Xeris Biopharma Holdings, Inc. (0001867096) (Issuer)
SAN DIEGO and BASEL, Switzerland , April 17, 2025 (GLOBE NEWSWIRE) -- Bright Peak Therapeutics, a clinical-stage biotechnology company focused on discovering and developing multifunctional immunotherapies for cancer, today announced the appointment of John Schmid, a seasoned biotechnology executive, to its Board of Directors. "It is a pleasure to welcome John to our Board," said Fredrik Wiklund, Chief Executive Officer of Bright Peak Therapeutics. "John brings decades of experience and an extensive track record of success in the biotech sector. His strategic insights and financial expertise will be instrumental as we advance our clinical pipeline and scale Bright Peak for long-term succ
Kenneth Johnson, PharmD, SVP Global Development & Medical Affairs to retire Xeris Biopharma Holdings, Inc. (NASDAQ:XERS), a growth-oriented biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies, today announced that Dr. Anh Nguyen has joined Xeris as Chief Medical Officer (CMO) succeeding Ken Johnson PharmD, SVP, Global Development and Medical Affairs who will retire April 1, 2025. Dr. Nguyen will develop and lead the entire product portfolio vision and strategic direction for the Medical, Regulatory, Preclinical and Clinical Development, and Pharmacovigilance functions, reporting to John Shannon, X
John Shannon, President and Chief Operating Officer, to succeed Paul Edick as new CEO and Board Director Transition timing aligns with the solid financial position of the Company, including consistently strong growth from its commercial franchise, healthy cash position, and the track record of its leadership team Q2 '24 total revenue is anticipated to exceed $47 million, representing more than 23% growth over last year Xeris Biopharma Holdings, Inc. (NASDAQ:XERS), a growth-oriented biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies, today announced a CEO succession plan effective August 1, 20
4 - Xeris Biopharma Holdings, Inc. (0001867096) (Issuer)
4 - Xeris Biopharma Holdings, Inc. (0001867096) (Issuer)
4 - Xeris Biopharma Holdings, Inc. (0001867096) (Issuer)
8-K - Xeris Biopharma Holdings, Inc. (0001867096) (Filer)
8-K - Xeris Biopharma Holdings, Inc. (0001867096) (Filer)
EFFECT - Xeris Biopharma Holdings, Inc. (0001867096) (Filer)